Celltex Therapeutics and Steadman Philippon Research Institute enter clinical research agreement
Celltex Therapeutics Corporation and Steadman Philippon Research Institute (SPRI)have entered a clinical research agreement, which includes funding from Celltex for a clinical research project that will study adult adipose-derived Mesenchymal Stem Cells (MSCs) and their application for anti-aging.
In this world-class partnership, Celltex will provide human MSCs isolated from fat tissue that are IRB approved and patient consented for use by SPRI. The SPRI lab will conduct invitro research studies at its newly-renovated and highly-equipped Center for Regenerative Sports Medicine (CRSM) lab in Vail, CO.
After receiving MSCs from Celltex, the SPRI team will culture, expand and bank the cells to proceed with research including characterization of Celltex MSCs and their potential sub-populations to determine functional defects accumulated during aging of cells and stem cell senescence at the nuclear and protein expression levels. The SPRI team will also study signaling pathways involved in MSCs and their physio-biological properties under stress conditions, tested for proliferation and differentiation potentials with platelet rich plasma and/or bone marrow aspirate concentrates priming effect.
“We are proud to collaborate with SPRI to further our mission of using MSCs in ways that improve quality of life,” says Celltex CEO David G. Eller. “Through this partnership, we will uncover the incredible possibilities our own Mesenchymal Stem Cells have for anti-aging, wellness and overall health. The medical community continues to explore how stem cell therapy can transform health. SPRI has a unique and talented team that will characterize MSCs to study their impact on aging and age-related pathologies to explore potential solutions through regenerative medicine research and clinical translation.”
About Steadman Philippon Research Institute
The Steadman Philippon Research Institute is recognized globally for its pioneering research in osteoarthritis, healing, surgery, and injury prevention and rehabilitation. Since 1993 SPRI’s database (one of the largest in existence) has been collecting the patient information that has led to significant treatment advances in these areas.
More Recent News
Houston company gets green light to study your own stem cells to prevent COVID-19
Promising news out of Houston from a company that got the FDA’s clearance to try to use a person’s own stem cells to prevent COVID-19. Celltex Therapeutics Corporation is also hoping the stem cells will help treat some of the more severe cases.Read More
Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19
Celltex Therapeutics obtains approval from FDA to evaluate Celltex’s Mesenchymal Stem Cells as prevention against COVID-19 and Medistar Corporation’s biodefense HVAC filter to destroy nearly 100% of the virusRead More